Lakozamid Pliva

Lacosamide, the active ingredient in Lakozamid Pliva, is a sodium channel blocker presented as an oral dosage form for oral use. It treats partial‑onset seizures and epilepsy in patients requiring antiepileptic therapy.

GNH USA supplies Lakozamid Pliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lakozamid Pliva is an antiepileptic drug that modulates neuronal excitability in seizure disorders.

- Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy. - Focal epilepsy: improves overall seizure control as adjunctive therapy. - Epilepsy (adjunctive): provides additional seizure reduction when combined with other antiepileptics.

Lakozamid Pliva may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate cranial pain. - Fatigue: increased tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Suicidal ideation: thoughts of self‑harm requiring immediate medical attention. - Cardiac conduction abnormalities: PR‑interval prolongation that may lead to arrhythmia. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes indicating possible liver injury. - Anaphylaxis: severe allergic reaction with breathing difficulty. - Respiratory depression: reduced breathing effort, especially with CNS depressants.

Before prescribing Lakozamid Pliva, clinicians should consider several safety aspects.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: evaluate ECG for PR‑interval changes before and during therapy. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concomitant CNS depressants: may increase sedation and respiratory depression. - Store at ambient temperature: keep in the original container, protect from moisture.

Lakozamid Pliva can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Class I antiarrhythmics: may exacerbate PR‑interval prolongation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations of lacosamide. - Strong CYP3A4 inducers (e.g., rifampin): reduce lacosamide effectiveness.

Moderate Interactions (Monitor Closely): - Other antiepileptics: may require dose adjustments to maintain seizure control. - Alcohol: can enhance central nervous system depression. - Serotonergic agents: rare risk of serotonin syndrome when combined.